Trials / Unknown
UnknownNCT04339725
Gut Microbiota Metagenomics for Chronic Liver Disease
Research Based on Gut Microbiota Metagenomics for Prevention of Chronic Liver Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,240 (actual)
- Sponsor
- Chuncheon Sacred Heart Hospital · Academic / Other
- Sex
- All
- Age
- 31 Years – 82 Years
- Healthy volunteers
- Accepted
Summary
Gut microbiota modulation has effect on chronic liver disease
Detailed description
Chronic liver disease has been known as a disease of the liver which lasts over a period of 6-month. It consists of inflammation, hepatitis, cirrhosis, hepatocellular carcinoma. Gut microbiota plays an important roles in the chronic liver disease. It can suppress the progression of the liver disease by moulation gut microbiota. The investigators are still evaluating the effect of gut microbiota on the liver disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | DNA extraction | Extraction fecal DNA and compare disease group to normal group |
Timeline
- Start date
- 2017-04-01
- Primary completion
- 2020-03-01
- Completion
- 2025-01-01
- First posted
- 2020-04-09
- Last updated
- 2020-04-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04339725. Inclusion in this directory is not an endorsement.